Logo image of ELYM

ELIEM THERAPEUTICS INC (ELYM) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ELYM - US28658R1068 - Common Stock

5.11 USD
-0.05 (-0.97%)
Last: 10/2/2024, 8:06:17 PM
5.1 USD
-0.01 (-0.2%)
After Hours: 10/2/2024, 8:06:17 PM
Fundamental Rating

3

Overall ELYM gets a fundamental rating of 3 out of 10. We evaluated ELYM against 525 industry peers in the Biotechnology industry. While ELYM has a great health rating, there are worries on its profitability. ELYM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year ELYM has reported negative net income.
  • ELYM had a positive operating cash flow in the past year.
  • ELYM had negative earnings in each of the past 5 years.
  • ELYM had a negative operating cash flow in each of the past 5 years.
ELYM Yearly Net Income VS EBIT VS OCF VS FCFELYM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

  • With a decent Return On Assets value of -28.40%, ELYM is doing good in the industry, outperforming 70.77% of the companies in the same industry.
  • ELYM has a better Return On Equity (-28.88%) than 80.11% of its industry peers.
Industry RankSector Rank
ROA -28.4%
ROE -28.88%
ROIC N/A
ROA(3y)-31.78%
ROA(5y)-44.63%
ROE(3y)-32.97%
ROE(5y)-48.21%
ROIC(3y)N/A
ROIC(5y)N/A
ELYM Yearly ROA, ROE, ROICELYM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

  • ELYM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELYM Yearly Profit, Operating, Gross MarginsELYM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ELYM has been increased compared to 1 year ago.
  • There is no outstanding debt for ELYM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ELYM Yearly Shares OutstandingELYM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
ELYM Yearly Total Debt VS Total AssetsELYM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

  • ELYM has an Altman-Z score of 53.84. This indicates that ELYM is financially healthy and has little risk of bankruptcy at the moment.
  • ELYM's Altman-Z score of 53.84 is amongst the best of the industry. ELYM outperforms 98.06% of its industry peers.
  • ELYM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 53.84
ROIC/WACCN/A
WACCN/A
ELYM Yearly LT Debt VS Equity VS FCFELYM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

  • ELYM has a Current Ratio of 60.41. This indicates that ELYM is financially healthy and has no problem in meeting its short term obligations.
  • ELYM's Current ratio of 60.41 is amongst the best of the industry. ELYM outperforms 100.00% of its industry peers.
  • ELYM has a Quick Ratio of 60.41. This indicates that ELYM is financially healthy and has no problem in meeting its short term obligations.
  • ELYM has a Quick ratio of 60.41. This is amongst the best in the industry. ELYM outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 60.41
Quick Ratio 60.41
ELYM Yearly Current Assets VS Current LiabilitesELYM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M

More info and screens

1

3. Growth

3.1 Past

  • The earnings per share for ELYM have decreased strongly by -27.15% in the last year.
EPS 1Y (TTM)-27.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-851.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 23.41% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60%
EPS Next 2Y23.41%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELYM Yearly EPS VS EstimatesELYM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • ELYM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELYM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELYM Price Earnings VS Forward Price EarningsELYM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELYM Per share dataELYM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ELYM's earnings are expected to grow with 23.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.41%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • ELYM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELIEM THERAPEUTICS INC / ELYM FAQ

What is the ChartMill fundamental rating of ELIEM THERAPEUTICS INC (ELYM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ELYM.


What is the valuation status for ELYM stock?

ChartMill assigns a valuation rating of 1 / 10 to ELIEM THERAPEUTICS INC (ELYM). This can be considered as Overvalued.


How profitable is ELIEM THERAPEUTICS INC (ELYM) stock?

ELIEM THERAPEUTICS INC (ELYM) has a profitability rating of 2 / 10.


Can you provide the financial health for ELYM stock?

The financial health rating of ELIEM THERAPEUTICS INC (ELYM) is 8 / 10.


What is the earnings growth outlook for ELIEM THERAPEUTICS INC?

The Earnings per Share (EPS) of ELIEM THERAPEUTICS INC (ELYM) is expected to grow by 60% in the next year.